Trademark applications and grants for Dusa Pharmaceuticals Inc. Dusa Pharmaceuticals Inc has 51 trademark applications. The latest application filed is for "BLU-U PRO"
Patent Application | Date |
---|---|
ADJUSTABLE ILLUMINATORS AND METHODS FOR PHOTODYNAMIC THERAPY AND DIAGNOSIS 20220040494 - 17/506849 BOYAJIAN; Thomas ;   et al. | 2022-02-10 |
METHODS FOR PHOTODYNAMIC THERAPY 20220008538 - 17/487698 Lundahl; Scott ;   et al. | 2022-01-13 |
METHODS FOR PHOTODYNAMIC THERAPY 20210085788 - 17/109311 LUNDAHL; Scott ;   et al. | 2021-03-25 |
METHOD AND APPARATUS FOR APPLYING A TOPICAL SOLUTION 20210001101 - 17/027872 BOYAJIAN; Thomas ;   et al. | 2021-01-07 |
METHOD OF ADMINISTERING 5-AMINOLEVULINIC ACID (ALA) TO A PATIENT 20200398071 - 17/009871 BOYAJIAN; Thomas ;   et al. | 2020-12-24 |
NCAGE Code | 1ZBM3 | DUSA PHARMACEUTICALS, INC. |
CAGE Code | 1ZBM3 | DUSA PHARMACEUTICALS INC. |
S.A.M. Registration | 1ZBM3 [109234786] | DUSA PHARMACEUTICALS INC. |
DUNS | 109234786 | Dusa Pharmaceuticals, Inc. |
SEC | 0000879993 | DUSA PHARMACEUTICALS INC of NEW JERSEY |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.